Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey.

Breast Cancer (Dove Med Press) · 2026 · PMC13003651 · PMID 41868693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While progression-free survival (PFS) showed a numerical advantage for ET (6.0 vs 4.9 months), the difference did not reach statistical significance. Multivariate analysis confirmed both treatment type and de novo metastatic presentation as independent predictors of survival.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.